{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:43:45Z","timestamp":1769507025342,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02443-6","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T19:02:03Z","timestamp":1724094123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Chala","family":"Bashea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addisu","family":"Gize","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadesse","family":"Lejisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demiraw","family":"Bikila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betselot","family":"Zerihun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feyissa","family":"Challa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Melese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alganesh","family":"Gebreyohanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasahun","family":"Gorems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solomon","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gadissa Bedada","family":"Hundie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habteyes Hailu","family":"Tola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wondewosen","family":"Tsegaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"May","key":"2443_CR1","first-page":"1","volume":"8","author":"G Guo","year":"2020","unstructured":"Guo G, Ye L, Pan K, Chen Y, Xing D, Yan K, et al. New insights of emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention. Front Cell Dev Biol. 2020;8(May):1\u201322.","journal-title":"Front Cell Dev Biol"},{"key":"2443_CR2","unstructured":"WHO Coronavirus (COVID-19.) Dashboard. [Cited 2023 January 05]. https:\/\/covid19.who.int. 2024;2024."},{"issue":"10","key":"2443_CR3","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/ijbs.45053","volume":"16","author":"J Zheng","year":"2020","unstructured":"Zheng J. SARS-coV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16(10):1678\u201385.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"2443_CR4","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1080\/21645515.2020.1787068","volume":"16","author":"S Ezzikouri","year":"2020","unstructured":"Ezzikouri S, Nourlil J, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Coronavirus disease 2019\u2014historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum Vaccin Immunother. 2020;16(12):2992\u20133000.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"2443_CR5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.coviro.2011.10.012","volume":"1","author":"M Bolles","year":"2011","unstructured":"Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Curr Opin Virol. 2011;1(6):624\u201334.","journal-title":"Curr Opin Virol"},{"issue":"1","key":"2443_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"JFW Chan","year":"2020","unstructured":"Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221\u201336.","journal-title":"Emerg Microbes Infect"},{"issue":"546","key":"2443_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abc1931","volume":"12","author":"R Weissleder","year":"2020","unstructured":"Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med. 2020;12(546):1\u20136.","journal-title":"Sci Transl Med"},{"issue":"December","key":"2443_CR8","first-page":"1","volume":"11","author":"Y Galipeau","year":"2020","unstructured":"Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11(December):1\u201319.","journal-title":"Front Immunol"},{"issue":"6","key":"2443_CR9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.7326\/M20-7547","volume":"174","author":"I Arkhipova-Jenkins","year":"2021","unstructured":"Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021;174(6):811\u201321.","journal-title":"Ann Intern Med"},{"key":"2443_CR10","unstructured":"Martineau AR, Forouhi NG. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. Ann Oncol. 2020;(January):19\u201321."},{"key":"2443_CR11","doi-asserted-by":"crossref","unstructured":"Ntoumi F, Batchi-Bouyou A, Djontu J, Vouvoungui J, Mfoutou C, Ingoba L et al. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individuals. ResearchSquare. 2022:1\u201311.","DOI":"10.1186\/s12879-022-07593-y"},{"issue":"6","key":"2443_CR12","first-page":"1","volume":"36","author":"JH Yoo","year":"2021","unstructured":"Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 2021;36(6):1\u201317.","journal-title":"J Korean Med Sci"},{"key":"2443_CR13","unstructured":"CDC COVID-19 after Vaccination. Possible Breakthrough Infection. [Cited 2022 December 30]. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov 2023;2023."},{"issue":"11","key":"2443_CR14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","volume":"26","author":"AWD Edridge","year":"2020","unstructured":"Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26(11):1691\u20133.","journal-title":"Nat Med"},{"issue":"March","key":"2443_CR15","first-page":"1","volume":"12","author":"LN Yan","year":"2022","unstructured":"Yan LN, Liu PP, Li XG, Zhou SJ, Li H, Wang ZY, et al. Neutralizing antibodies and cellular immune responses against SARS-CoV-2 sustained one and a half years after natural infection. Front Microbiol. 2022;12(March):1\u201313.","journal-title":"Front Microbiol"},{"issue":"11","key":"2443_CR16","doi-asserted-by":"crossref","first-page":"e1517","DOI":"10.1016\/S2214-109X(21)00386-7","volume":"9","author":"EK Gudina","year":"2021","unstructured":"Gudina EK, Ali S, Girma E, Gize A, Tegene B, Hundie GB, et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities. Lancet Glob Health. 2021;9(11):e1517\u201327.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2443_CR17","first-page":"1","volume":"13","author":"H Ward","year":"2022","unstructured":"Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):1\u20136.","journal-title":"Nat Commun"},{"issue":"9","key":"2443_CR18","first-page":"1","volume":"9","author":"M Psichogiou","year":"2021","unstructured":"Psichogiou M, Karabinis A, Poulakou G, Antoniadou A, Kotanidou A, Degiannis D, et al. Comparative immunogenicity of BNT162b2 mRNA vaccine with natural SARS-CoV-2 infection. Vaccines (Basel). 2021;9(9):1\u201313.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"2443_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-022-02547-2","volume":"20","author":"M Karachaliou","year":"2022","unstructured":"Karachaliou M, Moncunill G, Espinosa A, Casta\u00f1o-Vinyals G, Rubio R, Vidal M, et al. SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia. BMC Med. 2022;20(1):1\u201316.","journal-title":"BMC Med"},{"issue":"24","key":"2443_CR20","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.","journal-title":"N Engl J Med"},{"issue":"6","key":"2443_CR21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/vaccines10060859","volume":"10","author":"T Gelanew","year":"2022","unstructured":"Gelanew T, Mulu A, Abebe M, Bates TA, Wassie L, Teferi M, et al. A single dose of ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of two-dose-vaccinated, SARS-CoV-2-infection-Na\u00efve individuals: a longitudinal study in Ethiopian health workers. Vaccines (Basel). 2022;10(6):859.","journal-title":"Vaccines (Basel)"},{"key":"2443_CR22","unstructured":"EPHI. Public Health Emergency Operation Center (PHEOC), Ethiopia COVID-19 pandemic preparedness and response in Ethiopia. Vol. 37, EPHI Weekly bulletin. 2022. Available from: https:\/\/www.ephi.gov.et\/images\/novel_coronavirus\/EPHI_-PHEOC_COVID-19_Weekly-bulletin_1_English_05042020.pdf"},{"key":"2443_CR23","unstructured":"Ethiopia-COVID-19 vaccine tracker. 5 vaccines approved for use in Ethiopia. https:\/\/covid19.trackvaccines.org\/country\/ethiopia\/ (accessed: June 2023)."},{"issue":"8","key":"2443_CR24","first-page":"1","volume":"10","author":"F Awartani","year":"2022","unstructured":"Awartani F, Qutob NM, Asia MR. Seroprevalence of SARS-CoV-2 antibodies among vaccinated and non-vaccinated adults in the West Bank: results of a repeated cross-sectional study. Vaccines (Basel). 2022;10(8):1\u201311.","journal-title":"Vaccines (Basel)"},{"key":"2443_CR25","unstructured":"Roche. Elecsys Anti-SARS-CoV-2 S Elecsys Anti-SARS-CoV-2 S. 2022;03:1\u20138."},{"key":"2443_CR26","unstructured":"Roche. Elecsys Anti-SARS-CoV-2 Elecsys Anti-SARS-CoV-2. 2022;4.0:1\u20136."},{"issue":"2","key":"2443_CR27","doi-asserted-by":"crossref","first-page":"E2255978","DOI":"10.1001\/jamanetworkopen.2022.55978","volume":"6","author":"J Briggs","year":"2023","unstructured":"Briggs J, Takahashi S, Nayebare P, Cuu G, Rek J, Zedi M, et al. Seroprevalence of antibodies to SARS-CoV-2 in rural households in Eastern Uganda, 2020\u20132022. JAMA Netw Open. 2023;6(2):E2255978.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2443_CR28","first-page":"1","volume":"9","author":"X Li","year":"2021","unstructured":"Li X, Liang C, Xiao X. SARS-CoV-2 neutralizing antibody levels post COVID-19 vaccination based on ELISA method\u2014A small real-world sample exploration. Vaccines (Basel). 2021;9(10):1\u201310.","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"2443_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003877","volume":"18","author":"MV Murhekar","year":"2021","unstructured":"Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June\u2013July 2021: a population-based cross-sectional study. PLoS Med. 2021;18(12):1\u201317.","journal-title":"PLoS Med"},{"issue":"4","key":"2443_CR30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cger.2021.05.001","volume":"37","author":"S Lin","year":"2021","unstructured":"Lin S, Kantor R, Clark E. Coronavirus disease 2019. Clin Geriatr Med. 2021;37(4):509\u201322.","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"2443_CR31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57\u201365.","journal-title":"Nat Rev Immunol"},{"key":"2443_CR32","doi-asserted-by":"crossref","unstructured":"Hussein AARM, Hashem MK, Azizeldine MG, Shaddad AM. Prevalence and characteristics of COVID 19 vaccine breakthrough infection in Upper Egypt. Egypt J Bronchol. 2023:0\u20137.","DOI":"10.1186\/s43168-023-00196-4"},{"key":"2443_CR33","doi-asserted-by":"crossref","unstructured":"Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021;13(10).","DOI":"10.7759\/cureus.19102"},{"issue":"44","key":"2443_CR34","first-page":"1539","volume":"70","author":"CH Bozio","year":"2021","unstructured":"Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, Natarajan K, Yang DH, Rao S, Klein NP, Irving SA. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19\u2013like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity\u2014nine states, January\u2013September 2021. MMWR. 2021;70(44):1539.","journal-title":"MMWR"},{"issue":"4","key":"2443_CR35","doi-asserted-by":"crossref","first-page":"115803","DOI":"10.1016\/j.diagmicrobio.2022.115803","volume":"104","author":"J Meyers","year":"2022","unstructured":"Meyers J, Windau A, Schmotzer C, Saade E, Noguez J, Stempak L, et al. SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassays. Diagn Microbiol Infect Dis. 2022;104(4):115803.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"February","key":"2443_CR36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2021.05.034","volume":"108","author":"M Sasikala","year":"2021","unstructured":"Sasikala M, Shashidhar J, Deepika G, Ravikanth V, Krishna VV, Sadhana Y, et al. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. Int J Infect. 2021;108(February):183\u20136.","journal-title":"Int J Infect"},{"issue":"1","key":"2443_CR37","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2666-5247(21)00275-5","volume":"3","author":"A Angyal","year":"2022","unstructured":"Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2022;3(1):e21\u201331.","journal-title":"Lancet Microbe"},{"key":"2443_CR38","first-page":"1","volume":"11","author":"P Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m P, Ballin M, Nordstr\u00f6m A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health - Europe. 2021;11:1\u20137.","journal-title":"Lancet Reg Health - Europe"},{"issue":"10295","key":"2443_CR39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","volume":"398","author":"AM Borobia","year":"2021","unstructured":"Borobia AM, Carcas AJ, P\u00e9rez-Olmeda M, Casta\u00f1o L, Bertran MJ, Garc\u00eda-P\u00e9rez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121\u201330.","journal-title":"Lancet"},{"issue":"4","key":"2443_CR40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/joim.13185","volume":"289","author":"MLL Madariaga","year":"2021","unstructured":"Madariaga MLL, Guthmiller JJ, Schrantz S, Jansen MO, Christensen C, Kumar M, et al. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. J Intern Med. 2021;289(4):559\u201373.","journal-title":"J Intern Med"},{"issue":"1","key":"2443_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-023-01263-z","volume":"23","author":"N Otsubo","year":"2023","unstructured":"Otsubo N, Fukuda T, Beppu H, Maki C, Yasui F, Hanawa T, et al. Reduced antibody response to SARS-CoV-2 in COVID-19 patients with newly diagnosed diabetes: a retrospective observational study. BMC Endocr Disord. 2023;23(1):1\u201311.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2443_CR42","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.resinv.2021.11.006","volume":"60","author":"M Hibino","year":"2022","unstructured":"Hibino M, Watanabe S, Tobe S, Maeda K, Horiuchi S, Nishiguchi S, et al. Antibody responses to SARS-CoV-2 nucleocapsid and spike proteins in hospitalized patients with COVID-19: a multicenter, retrospective, cross-sectional study in Japan. Respir Investig. 2022;60(2):256\u201363.","journal-title":"Respir Investig"},{"issue":"12","key":"2443_CR43","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1007\/s00125-020-05284-4","volume":"63","author":"V Lampasona","year":"2020","unstructured":"Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, Marzinotto I, et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020;63(12):2548\u201358.","journal-title":"Diabetologia"},{"issue":"8","key":"2443_CR44","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4239\/wjd.v6.i8.1073","volume":"6","author":"HE Tamez-P\u00e9rez","year":"2015","unstructured":"Tamez-P\u00e9rez HE. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073.","journal-title":"World J Diabetes"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02443-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T19:05:14Z","timestamp":1724094314000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02443-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02443-6","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from St. Paul\u2019s Hospital Millennium Medical College Institutional Review Board (SPHMMC-IRB: PM23\/253) and the Addis Ababa City Administration Health Bureau (AAHB\/4938\/227). Confidentiality of the collected information was assured by limiting data access to data collectors, data managers, and the principal investigator. Sensitive information that exposes the identity of the participants was not collected. All collected data were saved exclusively on the principal investigator\u2019s computer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent was obtained from the study participants that the result of the study would be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}